Maurizio Zazzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2559572/publications.pdf

Version: 2024-02-01

264	5,560	101543	138484
papers	citations	36	58
		h-index	g-index

273	273	273	5906
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. Infection, 2022, 50, 541-543.	4.7	10
2	Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV. International Journal of Antimicrobial Agents, 2022, 59, 106492.	2.5	6
3	Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study. Journal of Global Antimicrobial Resistance, 2022, , .	2.2	2
4	External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy. Scientific Reports, 2022, 12, 3291.	3.3	4
5	Effectiveness of integrase strand transfer inhibitors in HIVâ€infected treatmentâ€experienced individuals across Europe. HIV Medicine, 2022, , .	2.2	5
6	Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies. Clinical Microbiology and Infection, 2022, , .	6.0	5
7	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. Scientific Reports, 2022, 12, 5736.	3.3	6
8	Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study. Journal of Medical Virology, 2022, , .	5.0	1
9	Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters. Frontiers in Microbiology, 2022, 13, 846943.	3.5	15
10	Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. Vaccines, 2022, 10, 580.	4.4	2
11	SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility. Cells, 2022, 11, 1431.	4.1	11
12	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. Pathogens, 2022, 11, 546.	2.8	3
13	Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. Viruses, 2022, 14, 1374.	3.3	15
14	Enhancing care for people living with HIV: current and future monitoring approaches. Expert Review of Anti-Infective Therapy, 2021, 19, 443-456.	4.4	3
15	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	3.7	26
16	In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. Journal of Antimicrobial Chemotherapy, 2021, 76, 130-134.	3.0	12
17	Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells. Journal of General Virology, 2021, 102, .	2.9	1
18	Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro. International Journal of Molecular Sciences, 2021, 22, 2670.	4.1	4

#	Article	IF	Citations
19	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opinion on Therapeutic Patents, 2021, 31, 325-337.	5.0	84
20	Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases, 2021, 8, ofab103.	0.9	8
21	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. Journal of Antimicrobial Chemotherapy, 2021, 76, 1898-1906.	3.0	1
22	Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection. Open Forum Infectious Diseases, 2021, 8, ofab312.	0.9	4
23	Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. International Journal of Infectious Diseases, 2021, 108, 176-178.	3.3	26
24	Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. Viruses, 2021, 13, 1347.	3.3	12
25	Determinants of HIV-1 Late Presentation in Patients Followed in Europe. Pathogens, 2021, 10, 835.	2.8	23
26	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2394-2399.	3.0	6
27	BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. Life, 2021, 11, 896.	2.4	2
28	In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir. Journal of Antimicrobial Chemotherapy, 2021, 76, 3310-3312.	3.0	0
29	Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse. Aids, 2021, 35, 1708-1710.	2.2	0
30	Circulating SARS-CoV-2 variants in Italy, October 2020â€“March 2021. Virology Journal, 2021, 18, 168.	3.4	36
31	Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals. Journal of Infection, 2021, , .	3.3	3
32	Bithiazole Inhibitors of Phosphatidylinositol 4â€Kinase (PI4KIIIÎ²) as Broadâ€Spectrum Antivirals Blocking the Replication of SARSâ€CoVâ€2, Zika Virus, and Human Rhinoviruses. ChemMedChem, 2021, 16, 3548-3552.	3.2	13
33	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. Journal of Infection, 2021, 83, 467-472.	3.3	28
34	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. European Journal of Medicinal Chemistry, 2021, 224, 113683.	5.5	9
35	Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. International Journal of Infectious Diseases, 2021, 112, 40-44.	3.3	31
36	Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen. AIDS Research and Human Retroviruses, 2021, , .	1.1	0

#	Article	IF	Citations
37	Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019. Infezioni in Medicina, 2021, 29, 242-251.	1.1	0
38	Very late relapse in an HCV genotype 3-infected patient treated with direct-acting antivirals (DAA). Journal of Antimicrobial Chemotherapy, 2020, 75, 252-253.	3.0	1
39	Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. Journal of Antimicrobial Chemotherapy, 2020, 75, 194-199.	3.0	2
40	Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. Journal of Global Antimicrobial Resistance, 2020, 20, 163-169.	2.2	12
41	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. Open Forum Infectious Diseases, 2020, 7, ofaa456.	0.9	16
42	High CD45 expression of CD8+ and CD4+ T cells correlates with the size of HIV-1 reservoir in blood. Scientific Reports, 2020, 10, 20425.	3.3	8
43	Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. Molecules, 2020, 25, 5695.	3.8	64
44	Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012. Proceedings (mdpi), 2020, 50, .	0.2	0
45	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. Viruses, 2020, 12, 798.	3.3	46
46	Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses. Journal of Medicinal Chemistry, 2020, 63, 9876-9887.	6.4	7
47	DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins. European Journal of Medicinal Chemistry, 2020, 200, 112319.	5.5	27
48	Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. International Journal of Antimicrobial Agents, 2020, 56, 106027.	2.5	10
49	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2547-2553.	3.0	11
50	Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. SLAS Discovery, 2020, 25, 506-514.	2.7	13
51	5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein. ACS Medicinal Chemistry Letters, 2020, 11, 766-772.	2.8	5
52	Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. Viruses, 2020, 12, 641.	3.3	13
53	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, e24-e28.	2.1	3
54	(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity. ACS Infectious Diseases, 2020, 6, 687-702.	3.8	9

#	Article	IF	Citations
55	Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Research, 2020, 175, 104708.	4.1	30
56	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor. ACS Medicinal Chemistry Letters, 2020, 11, 956-962.	2.8	19
57	HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. Viruses, 2020, 12, 475.	3.3	20
58	Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. Infezioni in Medicina, 2020, 28, 576-586.	1.1	0
59	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.9	28
60	Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X. Molecules, 2019, 24, 3988.	3.8	31
61	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. Frontiers in Microbiology, 2019, 10, 769.	3.5	6
62	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes, 2019, 55, 290-297.	1.6	0
63	Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. International Journal of Antimicrobial Agents, 2019, 53, 515-519.	2.5	26
64	Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	15
65	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. Aids, 2019, 33, 315-326.	2.2	4
66	Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. PLoS ONE, 2019, 14, e0225381.	2.5	9
67	Hepatitis C Genotype 4 Virus Nonstructural 3 and Nonstructural 5A Resistance-associated Substitutions in a 16-year-old Adolescent Failing Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin. Pediatric Infectious Disease Journal, 2019, 38, e72-e74.	2.0	1
68	The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro. Journal of Antimicrobial Chemotherapy, 2019, 74, 607-613.	3.0	9
69	Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 614-617.	3.0	23
70	Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A. Journal of Clinical Virology, 2019, 111, 12-18.	3.1	6
71	Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein. ACS Medicinal Chemistry Letters, 2019, 10, 463-468.	2.8	9
72	Characterization of resistance profiles in HCV 2-3-4 DAA-naÃ¯ve and DAA-experienced infected patients in Italy. Digestive and Liver Disease, 2018, 50, 46-47.	0.9	0

#	Article	IF	Citations
73	National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing. Digestive and Liver Disease, 2018, 50, 55-56.	0.9	0
74	HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012. Scientific Reports, 2018, 8, 1702.	3.3	24
75	Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment. Aids, 2018, 32, 835-840.	2.2	1
76	Agreement between an inâ€house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to <scp>HIV</scp>â€1 protease, reverse transcriptase, and integrase inhibitors. Journal of Clinical Laboratory Analysis, 2018, 32, .	2.1	22
77	Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clinical Microbiology and Infection, 2018, 24, 308.e5-308.e8.	6.0	9
78	Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood. Clinical Chemistry and Laboratory Medicine, 2018, 56, e75-e77.	2.3	14
79	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. Journal of Hepatology, 2018, 68, 597-600.	3.7	28
80	Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains. ACS Chemical Biology, 2018, 13, 253-266.	3.4	13
81	Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro. Virus Research, 2018, 244, 64-70.	2.2	47
82	The global burden of HIV-1 drug resistance in the past 20 years. PeerJ, 2018, 6, e4848.	2.0	28
83	Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. Journal of Antimicrobial Chemotherapy, 2018, 73, 2480-2484.	3.0	15
84	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). Journal of Clinical Virology, 2018, 105, 112-117.	3.1	11
85	Evolution of transmitted HIVâ€1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. HIV Medicine, 2018, 19, 619-628.	2.2	34
86	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1â€“4 in Italy. Scientific Reports, 2018, 8, 8988.	3.3	36
87	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy113.	0.9	56
88	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. Journal of Antimicrobial Chemotherapy, 2018, 73, 2186-2196.	3.0	4
89	Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia. New Microbiologica, 2018, 41, 302-305.	0.1	3
90	Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA. Journal of Clinical Virology, 2017, 91, 18-24.	3.1	8

#	Article	IF	Citations
91	The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro. Aids, 2017, 31, 2307-2309.	2.2	12
92	Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs?. Frontiers in Immunology, 2017, 8, 1966.	4.8	3
93	Using drug exposure for predicting drug resistance â€“ A data-driven genotypic interpretation tool. PLoS ONE, 2017, 12, e0174992.	2.5	9
94	Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS ONE, 2017, 12, e0178942.	2.5	11
95	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS ONE, 2017, 12, e0187393.	2.5	11
96	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. AIDS Reviews, 2017, 19, .	1.0	5
97	Combining Kernel and Model Based Learning for HIV Therapy Selection. AMIA Summits on Translational Science Proceedings, 2017, 2017, 239-248.	0.4	12
98	Computer-Aided Optimization of Combined Anti-Retroviral Therapy for HIV: New Drugs, New Drug Targets and Drug Resistance. Current HIV Research, 2016, 14, 101-109.	0.5	18
99	HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. PLoS ONE, 2016, 11, e0146097.	2.5	25
100	Anticipating policy considerations for a future HIV vaccine: a preliminary study. Vaccine, 2016, 34, 3697-3701.	3.8	2
101	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology, 2016, 81, 82-89.	3.1	60
102	Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5388-5393.	7.1	100
103	Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. Journal of Clinical Virology, 2016, 83, 48-53.	3.1	5
104	Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection. Medicine (United States), 2016, 95, e3738.	1.0	18
105	Predicting human-immunodeficiency virus rebound after therapy initiation/switch using genetic, laboratory, and clinical data. , 2016, , .		1
106	The global spread of HIV-1 subtype B epidemic. Infection, Genetics and Evolution, 2016, 46, 169-179.	2.3	60
107	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	3.0	7
108	Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients. Journal of Clinical Virology, 2016, 76, 20-23.	3.1	4

#	Article	IF	Citations
109	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	3.0	4
110	Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. Journal of Antimicrobial Chemotherapy, 2016, 71, 367-371.	3.0	6
111	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clinical Infectious Diseases, 2016, 62, 655-663.	5.8	135
112	First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing. Journal of Clinical Virology, 2016, 78, 1-3.	3.1	4
113	Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. Journal of Antimicrobial Chemotherapy, 2015, 70, 1850-7.	3.0	12
114	Interplay Between Transmitted and Acquired HIV Type 1 Drug Resistance: Reasons for a Disconnect. Journal of Infectious Diseases, 2015, 212, 5-7.	4.0	7
115	Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania. AIDS Research and Human Retroviruses, 2015, 31, 448-451.	1.1	2
116	Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project). AIDS Research and Human Retroviruses, 2015, 31, 837-840.	1.1	6
117	Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR. Journal of Virological Methods, 2015, 224, 102-104.	2.1	2
118	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infectious Diseases, 2015, 2, ofv043.	0.9	30
119	Time on drug analysis based on real life data. Journal of the International AIDS Society, 2014, 17, 19790.	3.0	0
120	Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA. Journal of the International AIDS Society, 2014, 17, 19791.	3.0	4
121	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Journal of Medical Virology, 2014, 86, 1648-1655.	5.0	19
122	Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: Analysis from a national drug-resistance database (ARCA). Journal of Medical Virology, 2014, 86, 1459-1466.	5.0	2
123	Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIVâ€1 subtype C epidemics. Journal of Medical Virology, 2014, 86, 729-736.	5.0	29
124	Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men. Infection, Genetics and Evolution, 2014, 23, 176-181.	2.3	29
125	Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo. Journal of Virological Methods, 2014, 203, 102-106.	2.1	2
126	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection, 2014, 42, 61-71.	4.7	7

#	Article	IF	Citations
127	Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments. AIDS Research and Human Retroviruses, 2014, 30, 17-24.	1.1	5
128	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 735-741.	3.0	16
129	An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. Journal of Antimicrobial Chemotherapy, 2014, 69, 1104-1110.	3.0	13
130	Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003â€“2012 decade in Italy. BMC Infectious Diseases, 2014, 14, 398.	2.9	13
131	HIV tropism and its relationship with transmitted resistance in naive patients. Future Virology, 2013, 8, 815-820.	1.8	1
132	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. Infection, Genetics and Evolution, 2013, 19, 349-360.	2.3	4
133	Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism. BMC Infectious Diseases, 2013, 13, 508.	2.9	1
134	Drugâ€resistance development differs between <scp>HIV</scp>â€1â€infected patients failing firstâ€line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Medicine, 2013, 14, 571-577.	2.2	7
135	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Journal of Antimicrobial Chemotherapy, 2013, 68, 200-205.	3.0	14
136	RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics, 2013, 29, 1477-1480.	4.1	29
137	Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings. Journal of Antimicrobial Chemotherapy, 2013, 68, 1406-1414.	3.0	29
138	Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe. Journal of Infectious Diseases, 2013, 207, 1216-1220.	4.0	53
139	HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. Antimicrobial Agents and Chemotherapy, 2013, 57, 1053-1056.	3.2	39
140	Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. Clinical Microbiology and Infection, 2013, 19, 936-942.	6.0	10
141	Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infectious Diseases, 2013, 13, 537.	2.9	8
142	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. PLoS ONE, 2013, 8, e61436.	2.5	17
143	Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy. AIDS Research and Human Retroviruses, 2012, 28, 299-303.	1.1	2
144	Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort. Intervirology, 2012, 55, 160-166.	2.8	8

#	Article	IF	Citations
145	Interpretation of Genotypic Resistance to Predict Darunavir/Ritonavir Failure in Antiretroviral Experienced Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 170-172.	2.1	0
146	Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. Clinical Microbiology and Infection, 2012, 18, E66-E70.	6.0	5
147	Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naÃ¯ve and pretreated patients. Clinical Microbiology and Infection, 2012, 18, E428-E430.	6.0	22
148	Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes. AIDS Research and Therapy, 2012, 9, 13.	1.7	3
149	Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project. Intervirology, 2012, 55, 123-127.	2.8	43
150	Future research and collaboration: the â€œSINERGIEâ€•project on HCV (South Italian Network for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.9	12
151	HIV-1 Subtype F1 Epidemiological Networks among Italian Heterosexual Males Are Associated with Introduction Events from South America. PLoS ONE, 2012, 7, e42223.	2.5	22
152	Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. Journal of Antimicrobial Chemotherapy, 2012, 67, 984-987.	3.0	54
153	Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection, 2012, 40, 311-318.	4.7	19
154	Renewal Strategies for the Environmental Conversion of Crafts Districts in Italy. Procedia Engineering, 2011, 21, 771-779.	1.2	7
155	European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infectious Diseases, The, 2011, 11, 394-407.	9.1	218
156	HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance. Clinical Drug Investigation, 2011, 31, 345-349.	2.2	7
157	A novel methodology for large-scale phylogeny partition. Nature Communications, 2011, 2, 321.	12.8	118
158	Interpretation of Genotypic HIV-1 Resistance to Darunavir and Virological Response: Validation of Available Systems and of a New Score. Antiviral Therapy, 2011, 16, 489-497.	1.0	10
159	The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. Aids, 2011, 25, 1855-1863.	2.2	23
160	Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage. Antiviral Therapy, 2011, 16, 1035-1045.	1.0	23
161	Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Medicine, 2011, 12, 211-218.	2.2	32
162	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007â€“2009. Clinical Microbiology and Infection, 2011, 17, 1352-1355.	6.0	6

#	Article	IF	Citations
163	A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen. BMC Medical Informatics and Decision Making, 2011, 11, 40.	3.0	7
164	HIV-1 mutational pathways under multidrug therapy. AIDS Research and Therapy, 2011, 8, 26.	1.7	12
165	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. Journal of Medical Virology, 2011, 83, 391-398.	5.0	1
166	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	3.0	56
167	HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance. Clinical Drug Investigation, 2011, , 1.	2.2	4
168	Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Aids, 2010, 24, 365-371.	2.2	5
169	Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. Aids, 2010, 24, 1013-1018.	2.2	32
170	Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology, 2010, 7, 56.	2.0	50
171	Low rate of virological failure and maintenance of susceptibility to HIVâ€1 protease inhibitors with firstâ€line lopinavir/ritonavirâ€based antiretroviral treatment in clinical practice. Journal of Medical Virology, 2010, 82, 1996-2003.	5.0	6
172	Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). HIV Medicine, 2010, 11, 530-4.	2.2	7
173	Changing patterns in HIVâ€1 nonâ€B clade prevalence and diversity in Italy over three decades[*]. HIV Medicine, 2010, 11, 593-602.	2.2	54
174	Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy. Clinical Microbiology and Infection, 2010, 16, 848-851.	6.0	2
175	Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction. PLoS ONE, 2010, 5, e9044.	2.5	2
176	Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time. PLoS ONE, 2010, 5, e11505.	2.5	56
177	Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models. PLoS ONE, 2010, 5, e13753.	2.5	21
178	Impact of Remote versus Local Sampling on Sensitivity of Genotypic Antiretroviral Resistance Testing. Journal of Clinical Microbiology, 2010, 48, 2321-2322.	3.9	0
179	High Genetic Barrier Antiretroviral Drugs in Human Immunodeficiency Virusâ€"Positive Pregnancy. Clinical Infectious Diseases, 2010, 50, 895-897.	5.8	5
180	Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. Journal of Antimicrobial Chemotherapy, 2010, 65, 752-760.	3.0	5

#	Article	IF	Citations
181	Impact of extensive HIV-1 variability on molecular diagnosis in the Congo basin. Journal of Clinical Virology, 2010, 47, 372-375.	3.1	10
182	Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. Journal of Antimicrobial Chemotherapy, 2009, 64, 607-615.	3.0	33
183	Robust Supervised and Unsupervised Statistical Learning for HIV Type 1 Coreceptor Usage Analysis. AIDS Research and Human Retroviruses, 2009, 25, 305-314.	1.1	21
184	Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization. Bioinformatics, 2009, 25, 1040-1047.	4.1	10
185	Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. Journal of Antimicrobial Chemotherapy, 2009, 64, 616-624.	3.0	34
186	Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2phenoâ€THEO on a Large Clinical Database. Journal of Infectious Diseases, 2009, 199, 999-1006.	4.0	40
187	A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artificial Intelligence in Medicine, 2009, 47, 63-74.	6.5	55
188	Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: Predictors of virological response and drug resistance evolution in a multi-cohort study. Infection, 2009, 37, 438-444.	4.7	4
189	Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clinical Microbiology and Infection, 2009, 15, 93-97.	6.0	66
190	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology, 2009, 6, 49.	2.0	114
191	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antiviral Therapy, 2009, 14, 359-69.	1.0	8
192	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antiviral Therapy, 2009, 14, 433-42.	1.0	19
193	Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. Antiviral Therapy, 2009, 14, 273-283.	1.0	10
194	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antiviral Therapy, 2009, 14, 359-369.	1.0	14
195	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antiviral Therapy, 2009, 14, 433-442.	1.0	35
196	Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union. AIDS Research and Human Retroviruses, 2008, 24, 1319-1325.	1.1	22
197	Three-Class-Resistant Human Immunodeficiency Virus Type 1 Variant in a Drug-Naive Heterosexual Couple. Journal of Clinical Microbiology, 2008, 46, 3856-3859.	3.9	1
198	Acute Meningoencephalitis in Chronic HIV Infection: Clinical Resolution with Lopinavirâ€Ritonavirâ€“Containing Therapy. Clinical Infectious Diseases, 2008, 46, 1938-1938.	5.8	0

#	Article	IF	Citations
199	Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of human immunodeficiency virus type 1 unique recombinant forms. Journal of General Virology, 2008, 89, 3119-3125.	2.9	16
200	Selecting anti-HIV therapies based on a variety of genomic and clinical factors. Bioinformatics, 2008, 24, i399-i406.	4.1	50
201	Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy. PLoS ONE, 2008, 3, e3470.	2.5	45
202	Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients. Journal of Clinical Microbiology, 2007, 45, 3484-3484.	3.9	1
203	Cutaneous leishmaniasis: usefulnessof PCR on paraffin-embedded skin biopsies as part of routine investigation. Annals of Tropical Medicine and Parasitology, 2007, 101, 745-749.	1.6	15
204	Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients. Journal of Clinical Microbiology, 2007, 45, 1783-1788.	3.9	33
205	Use of Peripheral Blood DNA for Genotype Antiretroviral Resistance Testing in Drug-Naive HIV-Infected Subjects. Clinical Infectious Diseases, 2007, 44, 1657-1661.	5.8	26
206	Determinants of HIV-1 Genotypic Resistance to Darunavir (TMC114) in a Large Italian Resistance Database (Antiretroviral Resistance Cohort Analysis). Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 373-375.	2.1	1
207	Statistical Comparison of Machine Learning Techniques for Treatment Optimisation of Drug-Resistant HIV-1. Proceedings of the IEEE Symposium on Computer-Based Medical Systems, 2007, , .	0.0	0
208	Natural Variability in the HR-1 and HR-2 Domains of HIV Type 1 gp41 from Different Clades Circulating in Italy. AIDS Research and Human Retroviruses, 2007, 23, 558-563.	1.1	9
209	The development of artificial neural networks to predict virological response to combination HIV therapy. Antiviral Therapy, 2007, 12, 15-24.	1.0	26
210	Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy. Burns, 2006, 32, 348-351.	1.9	20
211	The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 352-360.	2.1	90
212	A child with vestibular neuritis. Is adenovirus implicated?. Brain and Development, 2006, 28, 410-412.	1.1	12
213	Frequency and Treatmentâ€Related Predictors of Thymidineâ€Analogue Mutation Patterns in HIVâ€1 Isolates after Unsuccessful Antiretroviral Therapy. Journal of Infectious Diseases, 2006, 193, 1219-1222.	4.0	26
214	Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antiviral Therapy, 2006, 11, 329-34.	1.0	8
215	Evidence of Differential Selection of HIV-1 Variants Carrying Drug-Resistant Mutations in Seroconverters. Antiviral Therapy, 2006, 11, 329-334.	1.0	16
216	Prevalence of Drugâ€Resistant HIVâ€1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. Journal of Infectious Diseases, 2005, 192, 958-966.	4.0	385

#	Article	IF	Citations
217	Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype. Journal of Clinical Virology, 2005, 32, 151-155.	3.1	8
218	Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication. Antimicrobial Agents and Chemotherapy, 2004, 48, 4611-4617.	3.2	20
219	Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. Journal of Antimicrobial Chemotherapy, 2004, 53, 356-360.	3.0	36
220	Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy, 2004, 9, 465-78.	1.0	20
221	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. Antiviral Therapy, 2004, 9, 465-478.	1.0	58
222	Long-term CD4+ T-Cell Response in HIV-1-Infected Patients Continuing Combination Antiretroviral Therapy Despite High-Level Viremia and Drug Resistance. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 69-71.	2.9	1
223	Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy. Journal of Medical Virology, 2003, 70, 506-512.	5.0	11
224	Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection. Clinical and Experimental Immunology, 2003, 132, 297-303.	2.6	26
225	Surrogate Markers as a Guide to Evaluate Response to Antiretroviral Therapy. Current Medicinal Chemistry, 2003, 10, 349-365.	2.4	20
226	Detection of a Drug-Resistant Human Immunodeficiency Virus Variant in a Newly Infected Heterosexual Couple. Clinical Infectious Diseases, 2002, 34, 116-117.	5.8	10
227	Broad Nucleosideâ€Analogue Resistance Implications for Human Immunodeficiency Virus Type 1 Reverseâ€Transcriptase Mutations at Codons 44 and 118. Journal of Infectious Diseases, 2002, 185, 898-904.	4.0	46
228	Immunoglobulin Gene Rearrangement Analysis in Composite Hodgkin Disease and Large B-Cell Lymphoma: Evidence for Receptor Revision of Immunoglobulin Heavy Chain Variable Region Genes in Hodgkin-Reed-Sternberg Cells?. Diagnostic Molecular Pathology, 2002, 11, 2-8.	2.1	46
229	Treatment with Lopinavir/Ritonavir in Heavily Pretreated Subjects Failing Multiple Antiretroviral Regimens in Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 533-535.	2.1	11
230	Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors. Journal of Clinical Virology, 2002, 25, 57-62.	3.1	20
231	Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. Journal of Medical Virology, 2002, 66, 143-150.	5.0	33
232	Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clinical and Experimental Immunology, 2002, 127, 486-494.	2.6	47
233	Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antiviral Therapy, 2002, 7, 245-50.	1.0	9
234	Divergent Distribution of HIV-1 Drug-Resistant Variants on and off Antiretroviral Therapy. Antiviral Therapy, 2002, 7, 245-250.	1.0	27

#	Article	IF	Citations
235	Extent of Human Immunodeficiency Virus Type 1 Drug Resistance as a Predictor of Virological Failure after Genotypeâ€Guided Treatment Switch. Clinical Infectious Diseases, 2001, 33, 706-709.	5.8	8
236	Dissociation of Responses to Highly Active Antiretroviral Therapy: Notwithstanding Virologic Failure and Virus Drug Resistance, Both CD4+ and CD8+ T Lymphocytes Recover in HIV-1 Perinatally Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 196-197.	2.1	7
237	Analysis of the HIV-1nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. , 2000, 60, 294-299.		15
238	Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of HIV-1 RNA in plasma. Journal of Virological Methods, 2000, 87, 91-97.	2.1	11
239	Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma Samples. Journal of Infectious Diseases, 2000, 181, 740-745.	4.0	106
240	High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2000, 16, 1379-1384.	1.1	18
241	Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. Aids, 2000, 14, 2204.	2.2	18
242	Evaluation of Cellâ€Free and Cellâ€Associated Peripheral Blood Human Immunodeficiency Virus Type 1 RNA Response to Antiretroviral Therapy. Journal of Infectious Diseases, 1999, 179, 361-366.	4.0	18
243	Antigenicity and Immunogenicity of the V3 Domain of HIV Type 1 Glycoprotein 120 Expressed on the Surface of Streptococcus gordonii. AIDS Research and Human Retroviruses, 1999, 15, 451-459.	1.1	39
244	Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients. , 1999, 57, 140-144.		33
245	Development and Significance of the HIV-1 Reverse Transcriptase M184V Mutation During Combination Therapy With Lamivudine, Zidovudine, and Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 203.	2.1	19
246	Clinical Evaluation of an In-House Reverse Transcription-Competitive PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. Journal of Clinical Microbiology, 1999, 37, 333-338.	3.9	10
247	Lack of efficacy of ozone therapy in HIV infection. Clinical Microbiology and Infection, 1998, 4, 667-669.	6.0	7
248	Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bone Marrow Transplantation, 1998, 22, 285-288.	2.4	66
249	Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Molecular Biotechnology, 1998, 10, 1-8.	2.4	22
250	HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Human Pathology, 1998, 29, 1285-1289.	2.0	55
251	Fatal Cytomegalovirus Infection in a Patient without Evidence of Prior Immunodeficiency. Clinical Infectious Diseases, 1998, 27, 659-660.	5.8	1
252	Focal myositis: A polymerase chain reaction analysis for a viral etiology. Human Pathology, 1997, 28, 111-113.	2.0	18

#	Article	IF	Citations
253	Lack of Evidence of HHV-8 DNA in Blood Cells From Heart Transplant Recipients. Blood, 1997, 89, 1837-1838.	1.4	3
254	Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. , 1997, 52, 20-25.		32
255	Neuronal intranuclear inclusion disease: Polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case. Acta Neuropathologica, 1996, 91, 215-218.	7.7	21
256	Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment. Infection, 1996, 24, 419-425.	4.7	15
257	Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 1011-1014.	2.9	0
258	Dosage of Tn916 Circular Intermediates in Enterococcus faecalis. Plasmid, 1995, 34, 48-57.	1.4	43
259	Increased reliability of selective PCR by using additionally mutated primers and a commercialTaq DNA polymerase enhancer. Molecular Biotechnology, 1995, 3, 166-169.	2.4	7
260	Identification of Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare by selective nested polymerase chain reaction. Molecular and Cellular Probes, 1995, 9, 321-326.	2.1	12
261	Low human immunodeficiency virus type 1 (HIV-1) DNA burden as a major cause for failure to detect HIV-1 DNA in clinical specimens by PCR. Journal of Clinical Microbiology, 1995, 33, 205-208.	3.9	20
262	Optimal conditions for detection of human immunodeficiency virus type 1 DNA by polymerase chain reaction with nested primers. Molecular and Cellular Probes, 1993, 7, 431-437.	2.1	14
263	Simultaneous Amplification of Multiple HIV-1 DNA Sequences from Clinical Specimens by Using Nested-Primer Polymerase Chain Reaction. AIDS Research and Human Retroviruses, 1993, 9, 315-320.	1.1	33
264	Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens. Journal of Medical Virology, 1992, 38, 172-174.	5.0	18